Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Allergan

McKesson

Walgreens

My investment management firm has a large position in the health care sector, and with AbbVie’s bid for Allergan earlier this week, it’s timely to review why we bought into this sector.

Here's Why Drug-Distribution and Pharmacy Stocks Are Bargains Now

Calithera Biosciences

Carnival

Denbury Resources

GigaMedia

Macerich

TG Therapeutics

Insiders may sell their stock for many reasons but they only buy it if believe they will profit. Here are 7 stocks to buy along with insiders.

7 Stocks on Sale the Insiders Are Buying

Gilead Sciences

AbbVie and Gilead shares have fallen considerably from their highs as serious concerns about future revenues have arisen.

AbbVie And Gilead - Two Different Strategies To Improve Growth

Immunomedics

Medicines

MGM Resorts

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.

Notable Insider Buys This Past Week: AbbVie, MGM and More

CenturyLink

Iron Mountain

Invesco

Macy's

Altria

Nielsen Hlds

Occidental Petroleum

AT&T

The names, the yields, and analysis on whether you can trust the dividends to be paid out for years.

The 10 Highest-Yielding Dividend Stocks in the S&P 500

Biogen

Mirati Therapeutics

These three biotech stocks should be outstanding long-term growth vehicles.

Three Top Biotech Stocks to Buy Right Now

AbbVie's Allergan deal isn't as bad as some might think.

4 Reasons to Buy AbbVie Now That It's Acquiring Allergan

AbbVie has announced a plan to acquire Allergan for more than $60 billion. This transaction has been fully financed and is expected to close in early-2020.

AbbVie And Allergan - Take Advantage Of AbbVie's Share Price Drop

Ser yourself up for profits with a bullish call option.

This Pharmaceutical Company is Oversold and Starting to Recover

AbbVie is dishing out $63 billion in stock and cash for Allergan, provided it gets regulatory approval.

Is Allergan a Good Deal for AbbVie?

Analysts offered mixed views Wednesday on AbbVie's $63 billion takeover of Botox-maker Allergan — a deal meant to lessen the pharmaceutical company's dependence on arthritis drug Humira.
The post AbbVie Is 'The New Cash King' As It Takes On Botox-Maker Allergan appeared first on Investor's Business Daily.

AbbVie Is 'The New Cash King' As It Takes On Botox-Maker Allergan

Enterprise Products Partners

Newell Brands

Tanger Factory Outlet Centers

The following seven dividend stocks have strong business models, durable competitive advantages, and high dividend yields above 5% that make them extremely attractive stocks for retirees, says Ben Reynolds, a contributor to MoneyShow.com, an income expert and editor of Sure Retirement.

7 Favorite Retirement Stocks With 5%+ Dividend Yields

FedEx

Micron Technology

Options trading was buzzing in AbbVie, FedEx and Micron Tuesday. Here are the metrics that matter moving forward.

Wednesday’s Vital Data: AbbVie, FedEx and Micron

AbbVie's buying Allergan for around $63 billion and shareholders from both companies are not on board.

Here's Why Nobody's Happy About This $63 Billion Buyout

AbbVie's deal to buy Allergan for about $63 billion is a "nice exit from a tough situation," RBC Capital Markets analyst Randall Stanicky says.

AbbVie deal may conclude a tumultuous 4 years for Botox-maker Allergan

AbbVie became the latest player to pursue a pharma megadeal.

AbbVie wants to acquire Allergan in the latest pharma megadeal

AbbVie (ABBV) is on the hunt for their next big revenue driver as their patent for the world???s top-selling drug, Humira, is nearing its end.

AbbVie + Allergan: Where Are The Synergies?

BlackBerry

Microsoft

AbbVie is buying Allergan, FedEx and Blackberry are reporting earnings and Microsoft is on the move. Here are our top stock trades.

5 Top Stock Trades for Wednesday June 26

AbbVie is buying Botox-maker Allergan in a $63 billion deal, the pharma giant announced Tuesday — sending Allergan stock rocketing. The deal comes as AbbVie's Humira faces biosimilars.

Pharma Buying Spree Continues As AbbVie Takes Out Allergan For $63 Billion

GlaxoSmithKline

Johnson & Johnson

These biopharma stocks to buy could also be a retiree's dream stocks.

3 Biopharma Stocks to Buy for Income

AbbVie announced Tuesday morning its intent to acquire Allergan for $63 billion.

AbbVie (ABBV) Stock Falls After $63 Billion Allergan Acquisition Announcement

Allergan agrees to a deal that values the stock at $188 per share for a 45% premium.

Allergan: Stay For The AbbVie Shares

AbbVie's roughly $63 billion cash and stock offer for Allergan has drawn skepticism, and traders will be watching these key levels.

AbbVie Stock Breaks Down After Acquisition

News of an AbbVie-Allergan deal has AGG stock heading higher on Tuesday with plans for the former company to acquire the latter.

News for AbbVie Stock (ABBV)